VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
INSPInspire Medical Systems, Inc.
$45.72$1.3B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksINSPCash Flow

Inspire Medical Systems, Inc. (INSP) Cash Flow Statement

10Y historyFree accessUpdated daily

Free cash flow remains highly volatile, swinging from a 25.9% margin in 2025Q3 to a 1.5% margin in 2026Q1, largely due to inconsistent working capital management and significant stock-based compensation.

INSP Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Cash from Operations136.53M116.98M130.25M24.65M11.57M-20.12M-53.05M-33.38M-18.69M-15.79M-17.95M
Operating CF Margin %-12.83%16.22%3.95%2.84%-8.62%-45.97%-40.68%-36.95%-55.28%-109.27%
Operating CF Growth %3839.63%-10.19%428.32%113.1%157.5%62.07%-58.93%-78.54%-18.38%12.02%-
Net Income131.14M145.42M53.51M-21.15M-44.88M-42.04M-57.2M-33.24M-21.83M-17.51M-18.53M
Depreciation & Amortization16.02M13.96M6.55M2.85M2.9M1.99M840K1.4M393K285K103K
Stock-Based Compensation129.93M0116.01M82.47M0012.82M01.22M243K248K
Deferred Taxes1.01M-88.75M0000-22K0-53K100K-195K
Other Non-Cash Items-84.48M133.73M-7.51M1.27M51.74M26.79M1.4M5.04M714K315K180K
Working Capital Changes-57.08M-87.38M-37.71M-40.78M1.81M-6.86M-10.88M-6.57M861K777K243K
Change in Receivables-12.21M-26.23M-2.6M-30.22M-27.02M-9.24M-11.84M-6.48M-2.84M-1.77M-760K
Change in Inventory-66.51M-65.17M-46.23M-22M5.34M-8.75M-2.65M-3.17M1M-315K612K
Change in Payables12.9M-3.75M604K9.3M14.36M4.78M2.05M1.03M439K1.82M-480K
Cash from Investing11.75M21.45M-113.12M-294.82M-19.6M29.14M86.63M-43.56M-83.39M-7.6M-306K
Capital Expenditures-39.82M-38.5M-39.12M-23.63M-9.1M-4.67M-2.46M-2.74M-250K-412K-306K
CapEx % of Revenue4.35%4.22%4.87%3.78%2.23%2%2.13%3.34%0.49%1.44%1.86%
Acquisitions000000-89.08M0000
Investments-----------
Other Investing0000-10.5M089.08M0-83.14M-7.19M0
Cash from Financing-103.17M-183.45M-52.39M13.95M235.08M14.95M134.06M2.5M190.38M25.66M12.81M
Debt Issued (Net)0000-24.5M0008M458K0
Equity Issued (Net)-91.73M-160.41M-47.23M31.11M259.62M14.95M134.06M2.5M182.38M25.2M12.81M
Dividends Paid00000000000
Share Repurchases-100.01M-175.02M-75M00000000
Other Financing-11.44M-23.04M-5.17M-17.16M-43K000000
Net Change in Cash45.05M-45.34M-35.39M-256.06M227.13M23.95M167.66M-74.43M88.33M2.27M-5.44M
Free Cash Flow96.71M78.48M91.12M1.02M2.47M-24.79M-55.5M-35.59M-18.94M-16.2M-18.25M
FCF Margin %10.57%8.61%11.35%0.16%0.61%-10.62%-48.1%-43.37%-37.44%-56.72%-111.13%
FCF Growth %22.65%-13.88%8798.73%-58.59%109.98%55.34%-55.96%-87.84%-16.92%11.24%-
FCF per Share3.372.642.980.030.09-0.91-2.13-1.49-1.30-1.20-1.46
FCF Conversion (FCF/Net Income)0.74x0.80x2.43x-1.17x-0.26x0.48x0.93x1.00x0.86x0.90x0.97x
Interest Paid133K022K02.32M1.89M02.03M000
Taxes Paid00000000000

Key Metrics

Growth RegimeDecelerating
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Elective procedure demand sensitivity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Compensation

As reported in recent financial filings, the relationship between net income and operating cash flow remains highly volatile, with the OCF/NI ratio fluctuating from -1.14 in 2026Q1 to 6.90 in 2025Q3, largely driven by significant non-cash stock-based compensation charges and erratic working capital movements.

The wide divergence between net income and operating cash flow suggests that GAAP earnings are currently an unreliable proxy for the company's actual cash-generating capacity. Investors should monitor the persistent reliance on stock-based compensation, which appears to be a structural feature of the expense base rather than a transitory item.

Free Cash Flow Volatility Persists

Based on the company's quarterly cash flow statements, free cash flow margins have exhibited extreme instability, swinging from a peak of 25.9% in 2025Q3 to a negative 7.5% in 2025Q1, reflecting the underlying difficulty in achieving consistent cash conversion during periods of aggressive commercial expansion.

The inability to maintain positive free cash flow suggests that the business model remains in a high-burn phase despite its maturity in the market. This trajectory warrants further investigation into whether the current cost structure can support sustainable cash generation without continued reliance on external capital or equity-based incentives.

Working Capital Swings Impede Liquidity

According to historical data, working capital changes have frequently acted as a significant drag on cash flow, with a notable $42.6M outflow in 2025Q2, indicating potential inefficiencies in inventory management or delays in the collection cycle as the company scales its U.S. commercial footprint.

The recurring negative impact of working capital on operating cash flow suggests that the company's rapid growth is consuming cash faster than it can be recovered from operations. This trend may indicate that the firm is building inventory in anticipation of demand that has yet to materialize, creating a potential liquidity risk.

Aggressive Capital Allocation Amidst Uncertainty

As evidenced by recent cash flow statements, the company has prioritized share repurchases, including $75M in 2025Q1 and 2024Q4, even while operating cash flow remained inconsistent, suggesting a management focus on supporting equity valuation rather than prioritizing internal cash preservation during periods of decelerating growth.

The decision to deploy significant cash toward share buybacks while operating cash flow is volatile appears aggressive and may limit the company's financial flexibility. Investors should monitor whether this capital allocation strategy remains sustainable if the current deceleration in revenue growth continues to pressure the firm's cash reserves.

INSP — Frequently Asked Questions

Quick answers to the most common questions about buying INSP stock.

How much cash does Inspire Medical Systems, Inc. (INSP) generate from operations?

Inspire Medical Systems, Inc. (INSP) generated $117.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Inspire Medical Systems, Inc.'s free cash flow?

Inspire Medical Systems, Inc. (INSP) generated $78.5M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Inspire Medical Systems, Inc.'s capital expenditure (CapEx)?

Inspire Medical Systems, Inc. (INSP) spent $38.5M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Inspire Medical Systems, Inc. distribute cash to shareholders?

In 2025, Inspire Medical Systems, Inc. (INSP) spent $175.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.